{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T04:12:35Z","timestamp":1791087155794,"version":"4.1.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology Retina"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1016\/j.oret.2024.10.005","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T11:31:35Z","timestamp":1729078295000},"page":"352-366","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Retinal Vasculopathy and Choroiditis after Pegcetacoplan Injection"],"prefix":"10.1016","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3586-1241","authenticated-orcid":false,"given":"Ankur","family":"Nahar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dean","family":"Eliott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert L.","family":"Avery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose","family":"Pulido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Ralph C.","family":"Eagle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline R.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Courtney","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatyana","family":"Milman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5585-9056","authenticated-orcid":false,"given":"Anna M.","family":"Stagner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.oret.2024.10.005_bib1","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/j.ophtha.2019.07.011","article-title":"Complement C3 inhibitor pegcetacoplan for geographic atrophy secondary to age-related macular degeneration: a randomized phase 2 Trial","volume":"127","author":"Liao","year":"2020","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.10.005_bib2","unstructured":"American Society of Retina Specialists. ASRS Research and Safety in Therapeutics (REST) Committee Update on Adverse Events Reports Associated with Syfovre."},{"key":"10.1016\/j.oret.2024.10.005_bib3","first-page":"9","article-title":"Retinal vasculitis after intravitreal pegcetacoplan: report from the ASRS Research and Safety in Therapeutics (ReST) Committee","volume":"8","author":"Witkin","year":"2024","journal-title":"J\u00a0Vitreoretin Dis"},{"key":"10.1016\/j.oret.2024.10.005_bib4","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1007\/s40265-021-01560-8","article-title":"Pegcetacoplan: first approval","volume":"81","author":"Hoy","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.oret.2024.10.005_bib5","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/IAE.0000000000001392","article-title":"The pathophysiology of geographic atrophy secondary to age-related macular degeneration and the complement pathway as a therapeutic target","volume":"37","author":"Boyer","year":"2017","journal-title":"Retina"},{"key":"10.1016\/j.oret.2024.10.005_bib6","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1146\/annurev-genom-090413-025610","article-title":"Age-related macular degeneration: genetics and biology coming together","volume":"15","author":"Fritsche","year":"2014","journal-title":"Annu Rev Genomics Hum Genet"},{"key":"10.1016\/j.oret.2024.10.005_bib7","doi-asserted-by":"crossref","first-page":"338","DOI":"10.3928\/23258160-20140605-01","article-title":"Severe bilateral ischemic retinal vasculitis following cataract surgery","volume":"45","author":"Nicholson","year":"2014","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.oret.2024.10.005_bib8","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ophtha.2015.03.016","article-title":"Postoperative hemorrhagic occlusive retinal vasculitis: expanding the clinical spectrum and possible association with vancomycin","volume":"122","author":"Witkin","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.10.005_bib9","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.ophtha.2016.11.042","article-title":"Vancomycin-associated hemorrhagic occlusive retinal vasculitis: clinical characteristics of 36 eyes","volume":"124","author":"Witkin","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.10.005_bib10","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1007\/s40123-024-00920-3","article-title":"Real-world safety outcomes with brolucizumab in neovascular age-related macular degeneration: findings from the IRIS\u00ae registry","volume":"13","author":"Zarbin","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.oret.2024.10.005_bib11","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/j.ophtha.2020.11.011","article-title":"Risk of inflammation, retinal vasculitis, and retinal occlusion-related events with brolucizumab: post hoc review of HAWK and HARRIER","volume":"128","author":"Mon\u00e9s","year":"2021","journal-title":"Ophthalmology"},{"key":"10.1016\/j.oret.2024.10.005_bib12","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/ICB.0000000000001158","article-title":"Catastrophic bilateral retinal vascular occulsion after intravitreal bevacizumab injection","volume":"17","author":"Ng","year":"2023","journal-title":"Retin Cases Brief Rep"},{"key":"10.1016\/j.oret.2024.10.005_bib13","series-title":"Package insert","year":"2024"},{"key":"10.1016\/j.oret.2024.10.005_bib14","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1080\/09273948.2019.1611874","article-title":"Rituximab-associated retinal occlusive vasculopathy: a case report and literature review","volume":"28","author":"Conrady","year":"2020","journal-title":"Ocul Immunol Inflamm"},{"key":"10.1016\/j.oret.2024.10.005_bib15","first-page":"160","article-title":"Intravitreal rituximab-associated retinal occlusive vasculitis","volume":"7","author":"McAllister","year":"2023","journal-title":"J\u00a0Vitreoretin Dis"},{"key":"10.1016\/j.oret.2024.10.005_bib16","series-title":"Package insert. Regeneron Pharmaceuticals","year":"2023"},{"key":"10.1016\/j.oret.2024.10.005_bib17","series-title":"Package insert","year":"2023"},{"key":"10.1016\/j.oret.2024.10.005_bib18","doi-asserted-by":"crossref","unstructured":"Jop de Vrieze. Suspicions Grow That Nanoparticles in Pfizer\u2019s COVID-19 Vaccine Trigger Rare Allergic Reactions. https:\/\/doi.org\/10.1126\/science.abg2359.","DOI":"10.1126\/science.abg2359"},{"key":"10.1016\/j.oret.2024.10.005_bib19","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1136\/jcp.2008.058289","article-title":"Drug-induced cutaneous pathology","volume":"62","author":"Ramdial","year":"2009","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.oret.2024.10.005_bib20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ajo.2018.01.030","article-title":"Vancomycin-associated hemorrhagic occlusive retinal vasculitis: a clinical-pathophysiological analysis","volume":"188","author":"Todorich","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.oret.2024.10.005_bib21","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1046\/j.1365-2222.2003.01718.x","article-title":"Mechanisms in cutaneous drug hypersensitivity reactions","volume":"33","author":"Friedmann","year":"2003","journal-title":"Clin Exp Allergy"},{"key":"10.1016\/j.oret.2024.10.005_bib22","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1007\/s40264-019-00825-2","article-title":"Mechanisms of severe cutaneous adverse reactions: recent advances","volume":"42","author":"Bell\u00f3n","year":"2019","journal-title":"Drug Saf"},{"key":"10.1016\/j.oret.2024.10.005_bib23","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/bjd.13683","article-title":"Histopathology of drug rash with eosinophilia and systemic symptoms syndrome: a morphological and phenotypical study","volume":"173","author":"Ortonne","year":"2015","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.oret.2024.10.005_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.2500\/108854196778645029","article-title":"Vancomycin-induced Stevens-Johnson syndrome","volume":"17","author":"Alexander","year":"1996","journal-title":"Allergy Asthma Proc"},{"key":"10.1016\/j.oret.2024.10.005_bib25","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1177\/106002809202601206","article-title":"Stevens-Johnson-type reaction with vancomycin treatment","volume":"26","author":"Laurencin","year":"1992","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.oret.2024.10.005_bib26","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s12959-015-0047-z","article-title":"Thrombosis in vasculitis: from pathogenesis to treatment","volume":"13","author":"Emmi","year":"2015","journal-title":"Thromb J"},{"key":"10.1016\/j.oret.2024.10.005_bib27","doi-asserted-by":"crossref","DOI":"10.5041\/RMMJ.10263","article-title":"Cocaine-induced vasculitis","volume":"7","author":"Berman","year":"2016","journal-title":"Rambam Maimonides Med J"},{"key":"10.1016\/j.oret.2024.10.005_bib28","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/MAJ.0b013e31822979f1","article-title":"Cocaine-induced thrombotic vasculopathy","volume":"342","author":"John","year":"2011","journal-title":"Am J Med Sci"},{"key":"10.1016\/j.oret.2024.10.005_bib29","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1182\/blood-2006-02-004945","article-title":"Eosinophils are a major intravascular location for tissue factor storage and exposure","volume":"109","author":"Moosbauer","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.oret.2024.10.005_bib30","doi-asserted-by":"crossref","first-page":"4804","DOI":"10.1167\/iovs.05-0604","article-title":"Acute aminoglycoside retinal toxicity in\u00a0vivo and in\u00a0vitro","volume":"46","author":"Hancock","year":"2005","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"10.1016\/j.oret.2024.10.005_bib31","doi-asserted-by":"crossref","first-page":"5241","DOI":"10.1126\/scitranslmed.abq5241","article-title":"Anti-brolucizumab immune response as one prerequisite for rare retinal vasculitis\/retinal vascular occlusion adverse events","volume":"15","author":"Karle","year":"2023","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.oret.2024.10.005_bib32","doi-asserted-by":"crossref","first-page":"5480","DOI":"10.4049\/jimmunol.165.10.5480","article-title":"Fas and Fas ligand expressed on cells of the immune system, not on the target tissue, control induction of experimental autoimmune uveitis","volume":"165","author":"Wahlsten","year":"2000","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.oret.2024.10.005_bib34","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1016\/j.ophtha.2020.04.017","article-title":"Retinal vasculitis and intraocular inflammation after intravitreal injection of brolucizumab","volume":"127","author":"Baumal","year":"2020","journal-title":"Ophthalmology"}],"container-title":["Ophthalmology Retina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024004767?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468653024004767?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T01:06:44Z","timestamp":1743815204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468653024004767"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["S2468653024004767"],"URL":"https:\/\/doi.org\/10.1016\/j.oret.2024.10.005","relation":{},"ISSN":["2468-6530"],"issn-type":[{"value":"2468-6530","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Retinal Vasculopathy and Choroiditis after Pegcetacoplan Injection","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology Retina","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.oret.2024.10.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 by the American Academy of Ophthalmology","name":"copyright","label":"Copyright"}]}}